Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Compañía farmacéutica británica busca nuevas moléculas en fase temprana con actividad antiinfecciosa

Resumen

Tipo:
Demanda Tecnológica
Referencia:
TRUK20160720001
Publicado:
21/07/2017
Caducidad:
23/01/2018
Resumen:
Una pyme farmacéutica británica busca nuevas moléculas pequeñas con actividad contra bacterias Gram negativas, especialmente cepas resistentes. La empresa está interesada en continuar con el desarrollo de estos nuevos compuestos para mejorar sus perfiles de eficacia y seguridad con vistas a licenciar las moléculas mejoradas a compañías farmacéuticas y lanzarlas al mercado. Se buscan universidades, institutos de investigación y pymes con el fin de establecer acuerdos de licencia o cooperación técnica.

Details

Tittle:
UK-based pharmaceutical SME seeks novel early stage molecules with anti-infective activity
Summary:
A UK-based pharmaceutical SME is looking for novel small molecules with activity again Gram negative bacteria, especially resistant strains. The SME will further develop these novel compounds to improve their efficacy and safety profiles with a view to licensing the improved molecules to larger pharmaceutical companies to take onto the market. The SME seeks to partner with Universities, Research Institutes and SMEs in the form of a licensing agreement or technical cooperation agreement.
Description:
The emergence of antibiotic resistant strains of bacteria has made the development of new anti-bacterial compounds a matter of urgency. This is particularly the case for Gram negative bacterial species such as Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter cloacae.

A UK-based drug discovery and development company with subsidiary companies specialising in oncology, immunology and anti-infectives, is looking to partner with Universities, Research Institutions and other SMEs who may have novel small molecules with activity against Gram negative bacteria, particularly with activity against Multi-Drug Resistant strains. They are also interested in novel targets for Gram negative bacteria with chemical starting matter. The SME is looking for very early stage small molecules that it can further develop the compounds by improving activity, drug-like properties and safety profiles. The company has expertise in medicinal chemistry, computational chemistry, microbiology, drug metabolism and pharmacokinetics, analytical and business development; and are able to add significant value to a compound /program with the capability of taking the asset through preclinical development as well as Phase 1 clinical trial stage with the aim of licensing on to a larger pharmaceutical company for further development and market registration.

It is envisaged that the partnership with the University, Research Institution or SME would be in the form of a licensing agreement, although technical cooperation agreements will also be considered where appropriate and the company is open to other forms of collaboration.
Technical Specification or Expertise Sought:
The UK-based SME is looking for novel small molecules with activity against Gram negative bacteria, especially multi-drug resistant strains. They are especially looking for molecules at a very early stage of development. As well as access to the molecules and their chemical structure data the SME would also require the data generated to date on activity and safety profiles.

The SME is looking for novel small molecule compounds against a validated target. They will also consider novel targets but will require additional chemistry data in order to pursue these compounds. The SME will not consider biological molecules such as peptides nor compounds that are not novel.

Partner sought

Type and Role of Partner Sought:
The UK-based SME is looking to partner with Universities, Research Institutions and other SMEs that have identified novel small molecules that have activity against Gram negative bacteria such as Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter cloacae and in particular multi-drug resistant strains.

The UK-based SME will develop these early-stage molecules through an optimisation process improving their activity and safety profiles. The SME will take these molecules up to Phase 1 clinical trials with the aim of then licensing them on to larger pharmaceutical companies for later stage clinical trials.

It is anticipated that these partnerships will take the form of a licensing agreement whereby the SME will in-license the novel small molecules from the partner. Alternatively a technical cooperation agreement will also be considered where appropriate.

Client

Type and Size of Client:
Industry SME 50-249
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English